BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
2/26/2025 4:21:38 AM | Browse: 81 | Download: 369
 |
Received |
|
2024-08-26 02:45 |
|
Peer-Review Started |
|
2024-09-05 01:40 |
|
First Decision by Editorial Office Director |
|
2024-12-29 02:05 |
|
Return for Revision |
|
2024-12-29 02:05 |
|
Revised |
|
2025-01-10 14:33 |
 |
Publication Fee Transferred |
|
|
|
Second Decision by Editor |
|
2025-02-10 02:33 |
|
Second Decision by Editor-in-Chief |
|
|
|
Final Decision by Editorial Office Director |
|
2025-02-10 04:56 |
|
Articles in Press |
|
2025-02-10 04:56 |
|
Edit the Manuscript by Language Editor |
|
|
|
Typeset the Manuscript |
|
2025-02-12 02:16 |
|
Publish the Manuscript Online |
|
2025-02-26 04:21 |
| ISSN |
1007-9327 (print) and 2219-2840 (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/ |
| Copyright |
© The Author(s) 2025. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Oncology |
| Manuscript Type |
Letter to the Editor |
| Article Title |
Nab-paclitaxel plus capecitabine as a first-line regimen for advanced biliary tract cancers: Feasible or not feasible?
|
| Manuscript Source |
Invited Manuscript |
| All Author List |
Jian-Qiang Chen and Xiang Lan |
| ORCID |
|
| Funding Agency and Grant Number |
|
| Corresponding Author |
Xiang Lan, MD, Department of Hepatobiliary Surgery, The First Affiliated Hospital of Chongqing Medical University, No. 1 Youyi Road, Yuanjiagang, Yuzhong District, Chongqing 400016, China. lanxiangkeyan@163.com |
| Key Words |
Nab-paclitaxel; Capecitabine; Biliary tract cancers; Systemic therapy; First-line regimen |
| Core Tip |
We investigated the development and efficacy of systemic therapy for advanced biliary tract cancers (BTCs) and concluded that paclitaxel plus capecitabine is a promising first-line regimen for advanced BTCs. |
| Publish Date |
2025-02-26 04:21 |
| Citation |
Chen JQ, Lan X. Nab-paclitaxel plus capecitabine as a first-line regimen for advanced biliary tract cancers: Feasible or not feasible? World J Gastroenterol 2025; 31(10): 100771 |
| URL |
https://www.wjgnet.com/1007-9327/full/v31/i10/100771.htm |
| DOI |
https://dx.doi.org/10.3748/wjg.v31.i10.100771 |
© 2004-2026 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
California Corporate Number: 3537345
